Patsnap Launches AI Agents to Extract SAR Data and Identify Lead Compounds From Small Molecule Patents

Skip to Content News Archives Economy Defence Energy Oil & Gas Renewables Electric Vehicles Mining Commodities Agriculture Real Estate Mortgages Mortgage Rates Finance Banking Insurance Fintech Cryptocurrency Defence Work Wealth Smart Money Wealth Management Investor Personal Finance Family Finance Retirement Taxes High Net Worth FP Comment Executive Women Puzzmo Newsletters Financial Times Business Essentials More Innovation Information Technology FP500 Podcasts Small Business Lives Told Tails Told Shopping Financial Post Store Obituaries Place a Notice Advertising Advertising With Us Advertising Solutions Postmedia Ad Manager Sponsorship Requests Classifieds Place a Classifieds ad Working Profile Settings My Subscriptions My Offers Newsletters Customer Service FAQ News Economy Energy Mining Real Estate Finance Defence Work Wealth Investor FP Comment Executive Women Puzzmo Newsletters Financial Times Business Essentials This advertisement has not loaded yet, but your article continues below.HomeBusiness Wire News ReleasesPMN Press ReleasesThis section is The content in this section is supplied by Business Wire for the purposes of distributing press releases on behalf of its clients. Postmedia has not reviewed the content. by Business Wire Patsnap Launches AI Agents to Extract SAR Data and Identify Lead Compounds From Small Molecule PatentsAuthor of the article:Lead Compound Analyzer and SAR Extractor help scientists identify likely lead compounds and turn patent-disclosed chemistry into structured, source-referenced data for drug discovery.THIS CONTENT IS RESERVED FOR SUBSCRIBERS ONLYSubscribe now to read the latest news in your city and across Canada.Exclusive articles from Barbara Shecter, Joe O'Connor, Gabriel Friedman, and others.Daily content from Financial Times, the world's leading global business publication.Unlimited online access to read articles from Financial Post, National Post and 15 news sites across Canada with one account.National Post ePaper, an electronic replica of the print edition to view on any device, share and comment on.Daily puzzles, including the New York Times Crossword.SUBSCRIBE TO UNLOCK MORE ARTICLESSubscribe now to read the latest news in your city and across Canada.Exclusive articles from Barbara Shecter, Joe O'Connor, Gabriel Friedman and others.Daily content from Financial Times, the world's leading global business publication.Unlimited online access to read articles from Financial Post, National Post and 15 news sites across Canada with one account.National Post ePaper, an electronic replica of the print edition to view on any device, share and comment on.Daily puzzles, including the New York Times Crossword.REGISTER / SIGN IN TO UNLOCK MORE ARTICLESCreate an account or sign in to continue with your reading experience.Access articles from across Canada with one account.Share your thoughts and join the conversation in the comments.Enjoy additional articles per month.Get email updates from your favourite authors.THIS ARTICLE IS FREE TO READ REGISTER TO UNLOCK.Create an account or sign in to continue with your reading experience.Access articles from across Canada with one accountShare your thoughts and join the conversation in the commentsEnjoy additional articles per monthGet email updates from your favourite authorsSign In or Create an AccountTORONTO — Patsnap today announced Lead Compound Analyzer and SAR Extractor, two AI agents in Patsnap Eureka Life Sciences that help drug discovery teams identify likely lead compounds and extract structure-activity data from small molecule patents. By reducing manual extraction, the agents help medicinal chemistry, competitive intelligence and computational teams assess competitor compounds, compare chemical series and inform further research. Learn more here.This advertisement has not loaded yet, but your article continues below.AI is giving drug discovery teams new ways to analyze compounds and guide molecular design, but those workflows depend on the experimental data available to them. Patents are often an early public source of new compounds, potency data and structure-activity relationships, yet that evidence remains difficult to reuse.Get the latest headlines, breaking news and columns.By signing up you consent to receive the above newsletter from Postmedia Network Inc.A welcome email is on its way. If you don't see it, please check your junk folder.The next issue of Top Stories will soon be in your inbox.We encountered an issue signing you up. Please try againCompound structures appear as images, activity values sit in tables and the legends that explain them can be pages apart. Connecting those details by hand takes time. The new agents help turn that scattered evidence into structured, source-referenced data that scientists can review and use in computational research.“Patents disclose valuable evidence about which compounds were made, how they were tested and what the results showed. Making that evidence usable still takes substantial scientific effort,” said Mark Davies, Head of Product, Life Sciences, at Patsnap. “These agents bring structures and activity data together, with references scientists can check, so teams can spend more time assessing the chemistry and deciding what to investigate next.”The two agents address complementary parts of this challenge:identifies up to 10 compounds most likely to be the lead in a small molecule patent, grouped by the strength of the biological evidence disclosed. Supporting rationale and source references help scientists assess the candidates and determine where further investigation is needed.processes up to 10 patents per task, connecting compound structures with reported activity values, targets and experimental context in a structured table. Patsnap’s optical chemical structure recognition (OCSR) model achieved 97% precision in testing across more than 420 randomly selected English-language patents, covering over 8,800 structures and 5,100 complete molecules. Separate confidence scores for structure and activity, alongside source references, help scientists review the extracted data and validate findings.Used together, the agents help teams assess likely lead compounds alongside the wider chemical series disclosed in patents, supporting competitor assessment and structure-activity analysis. They complement Patsnap Chemical and Synapse within Patsnap’s broader portfolio of chemistry, target and drug development intelligence.Davies will present “Patents In, SAR Out: Grounding Agents in Chemistry” at the AI Drug Discovery & Development Summit in Boston on 29 October.This advertisement has not loaded yet, but your article continues below.Both agents are available now. Drug discovery, competitive intelligence and computational chemistry teams can request a demonstration using patents relevant to their research here.Founded in Singapore in 2007, Patsnap is a leading global innovation intelligence company. Leveraging domain-specific AI agents and robust analytics tools, Patsnap empowers IP, R&D and Life Sciences teams to unlock insights, accelerate discoveries, and protect breakthroughs. Trusted by nearly 20,000 enterprises, law firms, and research institutions in over 50 countries, including one-third of the world’s largest R&D spenders, Patsnap transforms how organizations innovate and make critical decisions. Learn more at www.patsnap.com.View source version on businesswire.com: This advertisement has not loaded yet.Notice for the Postmedia NetworkThis website uses cookies to personalize your content (including ads), and allows us to analyze our traffic. Read more about cookies here. By continuing to use our site, you agree to our Terms of Use and Privacy Policy.